ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Islet Allotransplantation Into Pre-vascularized Sernova Cell PouchTM – Preliminary Results from the University of Chicago

P. J. Bachul1, P. E. Borek1, G. S. Generette1, A. Perez-Gutierrez1, K. Jayant1, K. Golab1, L. Basto1, L. Perea1, M. Tibudan1, C. Thomas2, L. Philipson2, J. Fung1, P. Witkowski1

1Surgery, University of Chicago, Chicago, IL, 2Medicine, University of Chicago, Chicago, IL

Meeting: 2021 American Transplant Congress

Abstract number: 57

Keywords: Bioengineering, Engraftment, Hyperglycemia, Islets

Topic: Clinical Science » Pancreas » Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas & Small Bowel

Session Type: Rapid Fire Oral Abstract

Date: Saturday, June 5, 2021

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:30pm-6:35pm

Location: Virtual

*Purpose: Previous first-in-human pilot study showed safety but the conditions did not allow for detectable islet function post-transplantation into the pre-vascularized Sernova Cell Pouches (SCPs) implanted subcutaneously. Herein, in the current Phase I/II study we tested clinically, islet engraftment in modified conditions after transplantation into the SCP.

*Methods: First, SCPs were implanted below the anterior rectus sheath in type 1 diabetes patients with severe hypoglycemia unawareness and no stimulated C-peptide. Three weeks later Thymoglobulin, tacrolimus, and mycophenolate were initiated. During the infusion, islets were suspended in the patient’s own serum instead of saline to provide an optimal microenviroment for engraftment. Islets with purity over 90% were transplanted. A sentinel pouch was excised for evaluation 3 months after each transplant. Islet graft function was monitored based on glucose control, C-peptide and insulin usage.

*Results: Early in the ongoing study, wound infection required SCP excision in one of six SCP implanted individuals. The two furthest advanced patients received two subsequent islet transplants into the SCPs resulting in persistent islet graft function (positive serum C-peptide). Peak serum C-peptide remains currently at a level of 0.4-0.48 ng/ml, at 6 and 3 months after the second transplant in first and second patient, respectively. Islet engraftment was 9-fold higher when the islet mass was reduced by half to 3,300IEQ/kg (0.8 ml of tissue) during the second transplant in both patients. In the first patient, glucose control improved as A1c decreased from 6.3 to 6.0, insulin requirements dropped by 23% and CGM Time Below Range (TBR) dropped from 12% to 5%. In the second patient A1c dropped from 10.3 to 7.6, insulin requirements dropped by 40% and Time Above Range dropped from 76% to 48%. None of the patients experienced severe hypoglycemic episodes after the second islet transplant. Of note, both patients lost initially 7-15% of body weight and maintained stable weight afterwards. Preserved islet anatomy and endocrine function were found on histopathological evaluation of the vascularized environment within excised sentinel pouches.

*Conclusions: Modified conditions resulted in persistent islet graft function after SCP transplantation. Limiting islet mass to 3,000IEQ/kg per transplant significantly improved islet engraftment into Sernova Cell Pouches.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Bachul PJ, Borek PE, Generette GS, Perez-Gutierrez A, Jayant K, Golab K, Basto L, Perea L, Tibudan M, Thomas C, Philipson L, Fung J, Witkowski P. Islet Allotransplantation Into Pre-vascularized Sernova Cell PouchTM – Preliminary Results from the University of Chicago [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/islet-allotransplantation-into-pre-vascularized-sernova-cell-pouchtm-preliminary-results-from-the-university-of-chicago/. Accessed May 29, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences